ACTG A5164(V 20)-ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS W/ACUTE OIS

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的目的是了解是否最好在患者接受OI（机会性感染）或BI（细菌感染）治疗时立即开始使用抗HIV药物，或者等到OI或BI治疗后再开始使用。 目前尚不清楚艾滋病毒药物是否会引起副作用，可能会使严重疾病的患者（如OI或BI患者）的问题恶化。 本研究的另一个目的是比较在OI或BI期间或之后开始使用HIV药物的安全性和有效性。 该子研究的目的是比较患者在接受呼吸道感染治疗时和停止呼吸道感染治疗后血液中某些HIV药物的水平。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objective of this study to learn whether it is better to start drugs that fight HIV right away, while a patient are being treated for an OI(opportunistic infection) or BI(bacterial infection), or wait until after the OI or BI has been treated. It is not known whether the HIV drugs cause side effects that could worsen the problems for seriously ill people such as those with OI or BI. Another purpose of this study is to compare the safety and effectiveness of the HIV drugs when started during or after an OI or BI. The purpose of the substudy is to compare the levels of some of the HIV drugs in the blood while a patient is receiving treatment for a respiratory infection and after they have stopped treatment for the respiratory infection.